Search Results

Fidaxomicin 200 mg  | 99.23%

TargetMol

Fidaxomicin is a semisynthetic macrolide antibiotic used to treat Clostridium difficile-associated diarrhea in adults. Fidaxomicin has minimal systemic absorption and has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent, acute liver injury.

More Information Supplier Page

Fidaxomicin 25 mg  | 99.23%

TargetMol

Fidaxomicin is a semisynthetic macrolide antibiotic used to treat Clostridium difficile-associated diarrhea in adults. Fidaxomicin has minimal systemic absorption and has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent, acute liver injury.

More Information Supplier Page

Onalespib 2 mg  | Purity Not Available

TargetMol

Onalespib is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates […]

More Information Supplier Page

Vadimezan 25 mg  | 98.50%

TargetMol

Vadimezan (NSC 640488) is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan(NSC 640488) induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.

More Information Supplier Page